<DOC>
	<DOC>NCT00332332</DOC>
	<brief_summary>The purpose of this study is to evaluate the use of etanercept (Enbrel®) in the treatment of psoriasis in patients for a period of up to 1 year.</brief_summary>
	<brief_title>Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>18 years of age or older at baseline Moderate to severe plaque psoriasis at baseline with a rating of moderate, marked or severe on the Physician Global Assessment (score of 3, 4 or 5) Able to start Enbrel (Etanercept) therapy per the approved product monograph Exclusion Criteria Active infections at the initiation of Enbrel therapy. Evidence of skin conditions (i.e. eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis. Psoralen plus ultraviolet A radiation (PUVA) within 4 weeks or ultraviolet light B (UVB) therapy within 2 weeks of study drug initiation. Oral retinoids, cyclosporine, methotrexate, or any other systemic antipsoriasis therapy within 4 weeks or efalizumab (Raptiva®) within 8 weeks of study drug initiation and during the study period. Topical Vitamin A or D analog preparations, or anthralin within 2 weeks of study drug initiation and during the study period. Have received Remicade® (infliximab), Humira® (adalimumab) or Amevive®(alefacept) within 3 months before the initiation of study medication or during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Phase IV</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Inflammation</keyword>
</DOC>